PTGS2 and sarcoma: Although some investigators have affirmed the correlation of COX-2 overexpression with poor prognosis in some sarcomas, including osteosarcoma [7]–[9], chondrosarcoma [6], and uterine leiomyosarcoma [10], other investigators have denied the association in bone and soft tissue sarcomas [24]–[29].